Literature DB >> 21615537

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.

Brad Moriyama, Oluwaseun Falade-Nwulia, Janice Leung, Scott R Penzak, Caroline JJingo, Xuan Huang, Stacey A Henning, Wyndham H Wilson, Thomas J Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21615537      PMCID： PMC3164277          DOI： 10.1111/j.1439-0507.2011.02016.x

Source DB:  PubMed          Journal:  Mycoses        ISSN： 0933-7407            Impact factor:   4.377


× No keyword cloud information.
  9 in total

Review 1.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Authors:  Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh
Journal:  Mycoses       Date:  2011-11-29       Impact factor: 4.377

2.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

3.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

4.  Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.

Authors:  Brad Moriyama; Paul F Jarosinski; William D Figg; Stacey A Henning; Robert L Danner; Scott R Penzak; Alan S Wayne; Thomas J Walsh
Journal:  Pharmacotherapy       Date:  2013-02-11       Impact factor: 4.705

Review 5.  CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Authors:  Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-02-07       Impact factor: 4.705

6.  Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.

Authors:  Lihua Yang; Lihua Yu; Xinxin Chen; Yanqun Hu; Bin Wang
Journal:  Med Sci Monit       Date:  2015-06-07

7.  The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life.

Authors:  Yu-Hang Zhang; Chen Chu; Shaopeng Wang; Lei Chen; Jing Lu; XiangYin Kong; Tao Huang; HaiPeng Li; Yu-Dong Cai
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

Review 8.  Comparison of clinical pharmacology of voriconazole and posaconazole.

Authors:  Beata M Sienkiewicz; Łukasz Łapiński; Anna Wiela-Hojeńska
Journal:  Contemp Oncol (Pozn)       Date:  2016-12-20

9.  Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.

Authors:  Beata Sienkiewicz; Donata Urbaniak-Kujda; Jarosław Dybko; Andrzej Dryś; Magdalena Hurkacz; Tomasz Wróbel; Anna Wiela-Hojeńska
Journal:  Pathol Oncol Res       Date:  2017-07-06       Impact factor: 3.201
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.